FDA Warns Shire About Vyvanse Marketing

Law360, New York (May 17, 2011, 9:15 PM EDT) -- The U.S. Food and Drug Administration earlier this month warned Shire PLC about misleading promotional materials for attention deficit hyperactivity disorder drug Vyvanse that did not include clearly visible risk information.

In a letter sent to the pharmaceutical company May 6 and posted on the agency's site Tuesday, the FDA admonished Shire for promotional magnets for Vyvanse that included clear plastic sleeves into which a Shire representative's business card was meant to be inserted. The legally mandated risk information, printed behind the sleeve, was obscured by...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.